Live
- Treating politician differently from ordinary criminal will violate Constitution: ED tells SC on CM Kejriwal's plea
- Adverse weather conditions may hit mango crops in UP: Experts
- Cong to snatch reservation from Dalits, says Union Minister Pralhad Joshi
- Congress tied hands of our soldiers, we gave them full freedom to retaliate: PM Modi
- Big B on being honoured with Mangeshkar Award: ‘Abhaar aur mera param saubhagya’
- Fashion Entrepreneur Fund opens up for pre registrations
- ICEA shares blueprint for India to become a global leader in chip value chain
- Meera Deosthale describes marriage as a ‘beautiful union yet huge responsibility’
- 1 in 4 Indians came across political content that turned out to be deepfake: Report
- Summer diet tips for mom-to-be to stay hydrated and healthy
Unapproved antibiotics consumption alarmingly high
More than 47 per cent of antibiotic formulations used in India's private sector in 2019 were not approved by the central drug regulator, according to a study published in The Lancet Regional Health-Southeast Asia.
New Delhi: More than 47 per cent of antibiotic formulations used in India's private sector in 2019 were not approved by the central drug regulator, according to a study published in The Lancet Regional Health-Southeast Asia.
The research also found that azithromycin 500mg tablet was the most consumed antibiotic formulation (7.6 per cent) in India, followed by cefixime 200 mg tablet (6.5 per cent) during the year. The researchers at Boston University, US and Public Health Foundation of India, New Delhi, examined the private sector antibiotic use, which contributes to 85-90 per cent of the total consumption in India.
The data was gathered from a panel of 9,000 stockists who store products from approximately 5,000 pharmaceutical companies. However, these data did not include the drugs dispensed through public facilities, though this is less than 15-20 per cent of all drug sales in the country as per studies and national health accounts estimates.
The researchers found a lower consumption rate of antibiotics compared to previous estimates, but very high relative consumption of broad-spectrum antibiotics, which act against a wide range of disease-causing bacteria.
